A Phase 1 interventional study of Belumosudil 200 mg tablet and [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose in Autoimmune Diseases and Fibrosis, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-26.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 63rd largest by enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2019, is one of 15 in phase 1, and was the 33rd registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 18+
Purespring Therapeutics Limited · Sites in United Kingdom, United States
Ages 18+
Imagine Institute · Sites in United Kingdom, Austria, Belgium and 8 more countries
Takeda · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18+
Immunovant Sciences GmbH · Sites in United Kingdom, United States, Argentina and 12 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 30 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 19 · Phase 3 24 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 94 across the 65 interventional studies, 2,424 across the 8 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 4 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Autoimmune Diseases with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
| NCT06193889Phase 3Kyverna TherapeuticsKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | 2027-09 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Human, absorption, metabolism and excretion study of belumosudil (KD025)
This is an open-label, 2-part study designed to assess the absolute bioavailability of belumosudil (KD025) and to determine the mass balance recovery, metabolite profile, and identification of metabolite structures for [14C]-KD025 in healthy male subjects.
Primary Objectives
Secondary Objectives
PART 1:
Part 1 is an open-label, non-randomized single oral dose followed by an IV microtracer assessment in 5 healthy male subjects. Subjects receive a single oral dose of belumosudil (KD025) 200 mg Tablet (Treatment A), in the fed state following a standard breakfast on the morning of Day 1. Subjects then receive an IV dose of 100 μg [14C]-KD025 (a 'microdose') containing not more than (NMT) 37 kBq (kilobecquerel; 1000 nanocurie [nCi]) [14C], as a 15 min IV infusion (Treatment B), beginning 1.75 hours (h) after the oral dose administration (Treatment A), i.e., 15 minutes [min] before the expected time of maximum concentration [Tmax] 2 h) for the oral dose.
Planned enrollment is to be 6 subjects to ensure 4 evaluable subjects. An evaluable subject for Part 1 will be defined as a subject who had sufficient data for evaluation of the primary oral bioavailability objective of the study.
All subjects are to undergo preliminary screening procedures to determine their eligibility for Part 1 and Part 2 at the screening visit (Day -28 to Day -2 of Part 1). Subjects are to be admitted to the clinical unit on the evening prior to investigational medicinal product (IMP) administration (Day -1 of Part 1) for confirmation of eligibility and baseline procedures. Subjects will be dosed on the morning following admission (Day 1 of Part 1). Following an overnight fast (approximately 10 h), subjects are to consume a standard breakfast and receive a single dose of Belumosudil 200 mg Tablet (Treatment A) 30 min after the start of breakfast. At 1 h 45 min (1.75 h) after Treatment A administration, subjects are to receive an IV infusion of [14C]-KD025 solution, 100 µg (Treatment B). Subjects are to remain resident in the clinic until up to 48 hours post-oral dose (up to Day 3). The minimum washout period between dose administrations in Part 1 and 2 is 7 days.
PART 2:
Part 2 is an open-label, non-randomized absorption, distribution, metabolism, and elimination (ADME) assessment in 5 healthy male subjects. Following a minimum washout period of 7 days, subjects who participated in Part 1 of the study are to be admitted to the clinical unit for participation in Part 2 of the study. Subjects are to receive a single oral administration of [14C]-KD025 200 mg Capsule containing NMT 9.8 MBq (266 µCi) [14C] (Treatment C) in the fed state following a standard breakfast on the morning of Day 1.
A subject in Part 2 will be considered evaluable if they had provided biological samples for up to 168 hours after drug administration or demonstrates >90% mass balance recovery, or \< 1% of the administered dose eliminated in excreta for 2 consecutive days, whichever was sooner.
Approximately 7 days after subjects are discharged from Part 1 of the study, subjects are to be admitted to the clinical unit on the evening of the day prior to IMP administration (Day -1 of Part 2) for confirmation of eligibility and baseline procedures.
Subjects are to be dosed on the morning following admission (Day 1 of Part 2). Following an overnight fast (approximately 10 h), subjects consume a standard breakfast and receive a single dose of [14C]-KD025 200 mg Capsule (Treatment C) 30 min after the start of breakfast. Subjects are to remain in the clinic until up to 168 hours after dosing (up to Day 8 of Part 2). The plan is for subjects to be released as a group when all subjects had achieved a mass balance cumulative recovery of > 90% or if \< 1% of the dose administered had been collected in urine and feces within 2 separate consecutive 24-hour periods. This may result in the subjects being discharged as a group prior to completion of the planned residency period. Once the discharge criteria or the planned residency period is achieved, the subjects are to undergo discharge assessments; collection of all samples (blood, urine and feces) is stopped.
If mass balance criteria has not been met by all subjects on Day 8, the residency period for the subjects not achieving the release criteria may be extended up to a maximum of 216 h post-dose (Day 10 of Part 2). During the additional residency period, only urine and/or feces are to be collected. If the criterion is still not met by Day 10, or if additional residency not considered appropriate or necessary, then home collections of urine and/or feces may be requested at the discretion of the Investigator for individual subjects. To ensure ongoing well-being of subjects, a follow-up phone call will take place 5 to 7 days post-discharge from the study or after the end of the last collection period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition to the above criteria, subjects must agree to the following restrictions:
Exclusion Criteria:
Subject has a history or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belumosudil 200 mg tablet
Drug: Belumosudil 200 mg tablet
\[14C\]-KD025 at a dose of 100 μg in a 5 mL solution containing NMT 37 kBq (1000 nCi) \[14C\] over 15 min IV
Drug: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
\[14C\]-KD025 200 mg capsule containing NMT 9.8 MBq (215 μCi)
Drug: [14C]-KD025 200 mg capsule
Belumosudil 200 mg tablet, development candidate
Also known as: Rezurock (brand name), KD025, SLx-2119
test investigational medicinal product
test investigational medicinal product
Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV
Apparent terminal elimination half-life (t\[1/2\] for Part 1: (Treatment A) KD025 200 mg tablet, fed (Day 1). then 1.75 hours later (Treatment B) \[14C\]-KD025 solution for infusion 20 microgm/mL (100 microgm in 5 mL) containing \<= 37 kilobecquerel as 15 min IV infusion 100 microgm, fed
Time frame: Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1,1.5,2,3,4,5,6,8,10,12,22,34, and 46 h
Part 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD025
Part 1: Time of maximum plasma concentration (Tmax) for belumosudil 200 mg oral tablet and \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
Time frame: Plasma samples belumosudil relative oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 h
Part 1 Pharmacokinetics: Cmax of Belumosudil Tablets
The maximum concentration (Cmax) of belumosudil 200 mg tablets
Time frame: Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Part 1 Pharmacokinetics: Cmax of [14C]-KD025 IV
The maximum concentration (Cmax) of belumosudil \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
Time frame: Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,46 hours post-dose
Part 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets
The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of belumosudil 200 mg tablets
Time frame: Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Part 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV
The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
Time frame: Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 hours post-dose
Part 1: Absolute Bioavailability of Belumosudil 200 mg Tablet
The absolute bioavailability following oral administration of belumosudil 200 mg tablet, based on the area under the concentration-time curve from zero dosing extrapolated to infinity (AUC\[0-inf\])
Time frame: Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Part 2: Mass Balance Recovery Following 200 mg Oral Dose of [14C]-KD025 Capsule
Cumulative amount of total radioactivity excreted and recovered in urine, feces and total excreta (urine and feces combined) following dosing with \[14C\]-KD025 200 mg oral capsule.
Time frame: Cumulative sample collection time frame 0-6 hours, 0-12 hours, 0-24 hours, 0-48 hours, 0-72 hours, 0-96 hours, 0-120 hours, 0-144 hours, 0-168 hours, 0-192 hours, 0-216 hours post-dose
Part 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD025
Time of maximum concentration (Tmax) following a single oral dose of 200 mg \[14C\]-KD025 capsule
Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Part 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD025
Apparent terminal elimination half-life (t\[1/2\]) following a single oral dose of 200 mg \[14C\]-KD025 capsule
Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Part 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD025
Maximum concentration following a single oral dose of 200 mg \[14C\]-KD025 capsule
Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Part 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD025
Area under the concentration-time curve from zero dosing extrapolated to infinity following a single oral dose of 200 mg \[14C\]-KD025 capsule
Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
| Milestone | All Subjects (Part 1 and Part 2) |
|---|---|
| Started | 5 |
| Completed part 1 | 5 |
| Completed part 2 | 5 |
| Completed | 5 |
| Not completed | 0 |
Apparent terminal elimination half-life (t\[1/2\] for Part 1: (Treatment A) KD025 200 mg tablet, fed (Day 1). then 1.75 hours later (Treatment B) \[14C\]-KD025 solution for infusion 20 microgm/mL (100 microgm in 5 mL) containing \<= 37 kilobecquerel as 15 min IV infusion 100 microgm, fed
| Hours | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV | 5.298 ± 66.7 | 5.857 ± 35.8 |
Part 1: Time of maximum plasma concentration (Tmax) for belumosudil 200 mg oral tablet and \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
| Hours | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Part 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD025 | 2.000 (1.00 to 4.00) | 0.248 (0.24 to 0.25) |
The maximum concentration (Cmax) of belumosudil 200 mg tablets
| ng/mL | Part 1 Treatment A |
|---|---|
| Part 1 Pharmacokinetics: Cmax of Belumosudil Tablets | 1870 ± 36.7 |
The maximum concentration (Cmax) of belumosudil \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
| (pg/mL)/(ng equiv/mL) | Part 1: Treatment B |
|---|---|
| Part 1 Pharmacokinetics: Cmax of [14C]-KD025 IV | 4480 ± 18.0 |
The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of belumosudil 200 mg tablets
| (ng*h)/mL | Part 1 Treatment A |
|---|---|
| Part 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets | 8300 ± 40.2 |
The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV
| ((ng*h)/mL)/(ng equiv*h/mL) | Part 1: Treatment B |
|---|---|
| Part 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV | 6480 ± 29.3 |
The absolute bioavailability following oral administration of belumosudil 200 mg tablet, based on the area under the concentration-time curve from zero dosing extrapolated to infinity (AUC\[0-inf\])
| Percentage | Part 1: Treatment A |
|---|---|
| Part 1: Absolute Bioavailability of Belumosudil 200 mg Tablet | 64 |
Cumulative amount of total radioactivity excreted and recovered in urine, feces and total excreta (urine and feces combined) following dosing with \[14C\]-KD025 200 mg oral capsule.
| Percentage | Cumulative Urine Ae(%) | Cumulative Feces Ae (%) | Cumulative Total Ae (%) |
|---|---|---|---|
| 0-6 (hours) | 2.194 | NA | NA |
| 0-12 (hours) | 3.343 | NA | NA |
| 0-24 (hours) | 3.773 | 27.431 | 31.203 |
| 0-48 (hours) | 3.933 | 75.499 | 79.432 |
| 0-72 (hours) | 3.958 | 81.597 | 85.555 |
| 0-96 (hours) | 3.966 | 83.044 | 87.010 |
| 0-120 (hours) | 3.972 | 84.070 | 88.042 |
| 0-144 (hours) | 3.976 | 84.340 | 88.315 |
| 0-168 (hours) | 3.977 | 84.436 | 88.413 |
| 0-192 (hours) | 3.979 | 84.493 | 84.472 |
| 0-216 (hours) | 3.980 | 84.553 | 88.533 |
Time of maximum concentration (Tmax) following a single oral dose of 200 mg \[14C\]-KD025 capsule
| Hours | [14C]-KD025 Oral 200 mg KD025 |
|---|---|
| Part 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD025 | 2.000 (1.50 to 2.05) |
Apparent terminal elimination half-life (t\[1/2\]) following a single oral dose of 200 mg \[14C\]-KD025 capsule
| Hours | [14C]-KD025 Oral 200 mg KD025 |
|---|---|
| Part 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD025 | 5.109 ± 37.9 |
Maximum concentration following a single oral dose of 200 mg \[14C\]-KD025 capsule
| ng/mL | [14C]-KD025 Oral 200 mg KD025 |
|---|---|
| Part 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD025 | 1680 ± 32.1 |
Area under the concentration-time curve from zero dosing extrapolated to infinity following a single oral dose of 200 mg \[14C\]-KD025 capsule
| (ng*h)/mL | [14C]-KD025 Oral 200 mg KD025 |
|---|---|
| Part 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD025 | 8100 ± 37.0 |
Collected over Up to 20 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | All Subjects |
|---|---|
| RashSkin and subcutaneous tissue disorders | 1/5 |
| Age, Continuous(Years) | All Subjects |
|---|---|
| Mean | 53.0 ± 8.7 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 0 |
| Male | 5 |
| Race (NIH/OMB)(Participants) | All Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Body Mass Index (kg/m^2)(kg/m^2) | All Subjects |
|---|---|
| Mean | 27.86 ± 3.06 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in May 2019, 1 month.
Results were first posted in Sep 2021, 2 years 3 months after primary completion.
Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 1 month is below that.
Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil